Vital Strategies in Narcolepsy: Improving Outcomes in Individuals Living With Excessive Daytime Sleepiness and Cataplexy 

Case Study: Management of Narcolepsy

MinuteCE®
ReachMD Healthcare Image
Media formats available:
Details
Episodes
Presenters
Related
Comments
  • Overview

    The 7 episodes in this program will help you understand how to identify early signs and symptoms of narcolepsy to achieve a timely diagnosis and to then effectively manage this condition. Our experts focus on a well-rounded diagnostic and management approach to address not only the physical but also psychosocial aspects of narcolepsy. 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Clete A. Kushida, MD, PhD
    Professor of Psychiatry and Behavioral Sciences
    Division Chief, Medical Director, Sleep Medicine
    Stanford University School of Medicine
    Stanford, CA

    Dr. Kushida has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: XWPharma
    Research: Avadel Pharmaceuticals

    Michael J. Thorpy, MD
    Director, Sleep‐Wake Disorders Center
    Montefiore Medical Center
    Professor of Neurology
    Albert Einstein College of Medicine
    Bronx, NY

    Dr. Thorpy has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting/Advisory Board: Alkermes, Avadel Pharmaceuticals, Axsome, Balance Therapeutics, Eisai Pharmaceuticals, Harmony Biosciences, LLC, Idorsia Pharmaceuticals, Jazz Pharmaceuticals, NLS Pharmaceutics, Suven Life Sciences Ltd., Takeda Pharmaceutical Co., Ltd, XWPharma

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Alison Kole has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Prerna Poojary has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Improve the accuracy and timing of diagnosing narcolepsy
    • Identify key questions and insights for improving the patient-provider relationship and shared decision-making in the management of narcolepsy 
    • Develop an evidence-based, comprehensive treatment plan for the management of excessive daytime sleepiness and cataplexy due to narcolepsy
  • Target Audience

    This activity has been designed to meet the educational needs of sleep specialists, neurologists, and pulmonologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with narcolepsy.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare

    Global Learning Collaborative (GLC) designates this MinuteCE activity for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .75 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .75 AAPA Category 1 CME credits. Approval is valid until July 31, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .75 contact hours/0.075 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-086-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)


    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research. 

    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC, is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.

  • Commercial Support

    This activity is supported by independent educational grants from Avadel CNS Pharmaceuticals, LLC and Harmony Biosciences, LLC. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC, Prova Education, and TotalCME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education and TotalCME, LLC, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Register

We're glad to see you're enjoying Prova Education…
but how about a more personalized experience?

Register for free